Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

1.

CDK2 and mTOR are direct molecular targets of isoangustone A in the suppression of human prostate cancer cell growth.

Lee E, Son JE, Byun S, Lee SJ, Kim YA, Liu K, Kim J, Lim SS, Park JH, Dong Z, Lee KW, Lee HJ.

Toxicol Appl Pharmacol. 2013 Oct 1;272(1):12-20. doi: 10.1016/j.taap.2013.04.030. Epub 2013 May 22.

PMID:
23707764
[PubMed - indexed for MEDLINE]
2.

Hexane/ethanol extract of Glycyrrhiza uralensis and its active compound isoangustone A induce G1 cycle arrest in DU145 human prostate and 4T1 murine mammary cancer cells.

Seon MR, Park SY, Kwon SJ, Lim SS, Choi HJ, Park H, Lim do Y, Kim JS, Lee CH, Kim J, Park JH.

J Nutr Biochem. 2012 Jan;23(1):85-92. doi: 10.1016/j.jnutbio.2010.11.010. Epub 2011 Mar 22.

PMID:
21429724
[PubMed - indexed for MEDLINE]
3.

Isoangustone A, a novel licorice compound, inhibits cell proliferation by targeting PI3K, MKK4, and MKK7 in human melanoma.

Song NR, Lee E, Byun S, Kim JE, Mottamal M, Park JH, Lim SS, Bode AM, Lee HJ, Lee KW, Dong Z.

Cancer Prev Res (Phila). 2013 Dec;6(12):1293-303. doi: 10.1158/1940-6207.CAPR-13-0134. Epub 2013 Oct 8.

PMID:
24104352
[PubMed - indexed for MEDLINE]
4.

Cell cycle exit during terminal erythroid differentiation is associated with accumulation of p27(Kip1) and inactivation of cdk2 kinase.

Hsieh FF, Barnett LA, Green WF, Freedman K, Matushansky I, Skoultchi AI, Kelley LL.

Blood. 2000 Oct 15;96(8):2746-54.

PMID:
11023508
[PubMed - indexed for MEDLINE]
Free Article
5.

A concentrated aglycone isoflavone preparation (GCP) that demonstrates potent anti-prostate cancer activity in vitro and in vivo.

Bemis DL, Capodice JL, Desai M, Buttyan R, Katz AE.

Clin Cancer Res. 2004 Aug 1;10(15):5282-92.

PMID:
15297432
[PubMed - indexed for MEDLINE]
Free Article
6.
7.

Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition.

Flores O, Wang Z, Knudsen KE, Burnstein KL.

Endocrinology. 2010 Mar;151(3):896-908. doi: 10.1210/en.2009-1116. Epub 2010 Feb 10.

PMID:
20147522
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Cell-permeable carboxyl-terminal p27(Kip1) peptide exhibits anti-tumor activity by inhibiting Pim-1 kinase.

Morishita D, Takami M, Yoshikawa S, Katayama R, Sato S, Kukimoto-Niino M, Umehara T, Shirouzu M, Sekimizu K, Yokoyama S, Fujita N.

J Biol Chem. 2011 Jan 28;286(4):2681-8. doi: 10.1074/jbc.M109.092452. Epub 2010 Nov 9.

PMID:
21062737
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

PI3K/mTOR inhibition can impair tumor invasion and metastasis in vivo despite a lack of antiproliferative action in vitro: implications for targeted therapy.

Wander SA, Zhao D, Besser AH, Hong F, Wei J, Ince TA, Milikowski C, Bishopric NH, Minn AJ, Creighton CJ, Slingerland JM.

Breast Cancer Res Treat. 2013 Apr;138(2):369-81. doi: 10.1007/s10549-012-2389-6. Epub 2013 Feb 21.

PMID:
23430223
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.

Charette N, De Saeger C, Lannoy V, Horsmans Y, Leclercq I, Stärkel P.

Mol Cancer. 2010 Sep 22;9:256. doi: 10.1186/1476-4598-9-256.

PMID:
20860815
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Inhibition of mTORC1 kinase activates Smads 1 and 5 but not Smad8 in human prostate cancer cells, mediating cytostatic response to rapamycin.

Wahdan-Alaswad RS, Bane KL, Song K, Shola DT, Garcia JA, Danielpour D.

Mol Cancer Res. 2012 Jun;10(6):821-33. doi: 10.1158/1541-7786.MCR-11-0615. Epub 2012 Mar 27.

PMID:
22452883
[PubMed - indexed for MEDLINE]
Free PMC Article
12.
13.
14.

Methylseleninic acid inhibits microvascular endothelial G1 cell cycle progression and decreases tumor microvessel density.

Wang Z, Hu H, Li G, Lee HJ, Jiang C, Kim SH, Lü J.

Int J Cancer. 2008 Jan 1;122(1):15-24.

PMID:
17847021
[PubMed - indexed for MEDLINE]
15.

Induction of cell cycle arrest and apoptosis in human prostate carcinoma cells by a recombinant adenovirus expressing p27(Kip1).

Katner AL, Hoang QB, Gootam P, Jaruga E, Ma Q, Gnarra J, Rayford W.

Prostate. 2002 Sep 15;53(1):77-87.

PMID:
12210483
[PubMed - indexed for MEDLINE]
16.

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency.

Lane HA, Beuvink I, Motoyama AB, Daly JM, Neve RM, Hynes NE.

Mol Cell Biol. 2000 May;20(9):3210-23.

PMID:
10757805
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Cyclin D1 overexpression induces progestin resistance in T-47D breast cancer cells despite p27(Kip1) association with cyclin E-Cdk2.

Musgrove EA, Hunter LJ, Lee CS, Swarbrick A, Hui R, Sutherland RL.

J Biol Chem. 2001 Dec 14;276(50):47675-83. Epub 2001 Oct 4.

PMID:
11590147
[PubMed - indexed for MEDLINE]
Free Article
18.

Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression.

Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL.

J Biol Chem. 2000 Aug 11;275(32):24500-5.

PMID:
10827191
[PubMed - indexed for MEDLINE]
Free Article
19.

Inositol hexaphosphate inhibits growth and induces G1 arrest and apoptotic death of androgen-dependent human prostate carcinoma LNCaP cells.

Agarwal C, Dhanalakshmi S, Singh RP, Agarwal R.

Neoplasia. 2004 Sep-Oct;6(5):646-59.

PMID:
15548374
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk